Germany's financial regulator BaFin denied the MiCAR crypto license to futurum bank AG, a subsidiary of Bitcoin Group SE that operates the bitcoin.de platform, after more than 15 months of review. This refusal forces bitcoin.de to suspend trading indefinitely, as the bank's existing banking license does not cover crypto services without MiCAR authorization. Bitcoin Group SE plans to outsource trading and custody to regulated German partners and relaunch a revamped bitcoin.de app within weeks. Investors should watch for the app's launch, partner agreements, and financial updates to see if the new model stabilizes revenue or slows losses.
The BaFin denial of the MiCAR license to Bitcoin Group SE's futurum bank and the resulting suspension of bitcoin.de trading provide context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's market snapshot as of Oct 07, 2026 02:32 WIB: out of 50 major cryptocurrencies priced on Pluang, 14 rose and 35 fell today. Notable movers include AVAX at Rp203.055 with a 4.07% increase and a typical hold time of 87 days, BAT at Rp1.798 down 4.01% with a 93-day hold, and EGLD at Rp79.685 down 3.58% with an 85-day hold time.
Neogen reported earnings per share of $0.08 and revenue of $222.8 million, both exceeding analyst expectations. The company also announced a strategic partnership with Hinalea Imaging Corp. to develop digital food safety tools. However, Neogen's stoc...
PepsiCo is set to report its Q3 2026 earnings with expectations of $2.29 EPS and $25 billion revenue. The company faces challenges in North America, where organic revenue declined due to pricing pressures and changing consumer preferences. To adapt, ...
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
